ArticleMolecular therapy. Nucleic acids2019
LINC00472 Acts as a Tumor Suppressor in NSCLC through KLLN-Mediated p53-Signaling Pathway via MicroRNA-149-3p and MicroRNA-4270.
Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Effect of miR-4270 Suppression on Migration in Hepatocellular Carcinoma Cell Line (HepG2)Iranian biomedical journal · 2023Article
- DDX17 induces epithelial-mesenchymal transition and metastasis through the miR-149-3p/CYBRD1 pathway in colorectal cancer.Cell death & disease · 2023Article
- Article
- LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis.Cell death & disease · 2022Article
- Functional Screen for microRNAs Suppressing Anchorage-Independent Growth in Human Cervical Cancer Cells.International journal of molecular sciences · 2022Article
- Long non-coding RNA LINC00472 inhibits oral squamous cell carcinoma via miR-4311/GNG7 axis.Bioengineered · 2022Article
- LINC00472 suppresses oral squamous cell carcinoma growth by targeting miR-455-3p/ELF3 axis.Bioengineered · 2022Article
- Potential prognostic biomarkers related to immunity in clear cell renal cell carcinoma using bioinformatic strategy.Bioengineered · 2021Article
- Anticancer roles of let-7f-1-3p in non-small cell lung cancer via direct targeting of integrin β1.Experimental and therapeutic medicine · 2021Article
- Urinary exosomal long noncoding RNAs serve as biomarkers for early detection of non-small cell lung cancer.Bioscience reports · 2021Article
- LINC00472 suppressed by ZEB1 regulates the miR-23a-3p/FOXO3/BID axis to inhibit the progression of pancreatic cancer.Journal of cellular and molecular medicine · 2021Article
- MicroRNA‑149‑3p inhibits cell proliferation by targeting AKT2 in oral squamous cell carcinoma.Molecular medicine reports · 2021Article
- LINC00472 regulates vascular smooth muscle cell migration and proliferation via regulating miR-149-3p.Environmental science and pollution research international · 2021Article
- Article
- Long non-coding RNA maternally expressed gene regulates cigarette smoke extract induced lung inflammation and human bronchial epithelial apoptosis via miR-149-3p.Experimental and therapeutic medicine · 2021Article
- Comprehensive Analysis of Regulatory Network for LINC00472 in Clear Cell Renal Cell Carcinoma.Journal of healthcare engineering · 2021Article
- Crosstalk between Circulatory Microenvironment and Vascular Endothelial Cells in Acute Myocardial Infarction.Journal of inflammation research · 2021Article
- Long Noncoding RNA 00472: A Novel Biomarker in Human Diseases.Frontiers in pharmacology · 2021Review
- Gene expression profiling after LINC00472 overexpression in an NSCLC cell line1.Cancer biomarkers : section A of Disease markers · 2021Article
Corrections and comments
- Retraction · 2022-05-10Duplication of/in Image · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · · see also: https://pubpeer.com/publications/1FD3118518BE446C329DEFA0DEE61D
- Retracted
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs and microRNAs (miRNAs) have been reported to participate in the progression of non-small-cell lung cancer (NSCLC). Long intergenic non-protein-coding RNA 472 (LINC00472), miR-149-3p, and miR-4270 were found to be involved in tumor activities, suggesting potential roles in NSCLC. Thus, this study aimed to examine the ability of LINC00472 to influence the progression of NSCLC with the involvement of miR-149-3p and miR-4270. Initially, differentially expressed long non-coding RNAs (lncRNAs), downstream regulatory miRNAs, and genes related to NSCLC were identified. Next, the interaction among LINC00472, miR-149-3p and miR-4270, and KLLN and the p53-signaling pathway was determined. The effect of LINC00472 on the expression of E-cadherin, N-cadherin, and Vimentin was examined through gain-of-function and loss-of-function experiments. Lastly, the effects of LINC00472 on NSCLC tumor growth were assessed in vivo. LINC00472 and KLLN were found to exhibit low levels, while miR-149-3p and miR-4270 were highly expressed in NSCLC. In addition, the overexpression of LINC00472 was observed to upregulate KLLN and activate the p53-signaling pathway, which ultimately inhibited the invasion, migration, and EMT of NSCLC cells via miR-149-3p and miR-4270, corresponding to decreased N-cadherin and Vimentin and increased E-cadherin. The overexpression of LINC00472 exerted an inhibitory effect on tumor growth in vivo. Taken together, the key evidence suggests that the overexpression of LINC00472 can downregulate miR-149-3p and miR-4270 to upregulate KLLN and activate the p53-signaling pathway, thus inhibiting the development of NSCLC. This study highlights the potential of LINC00472 as a promising therapeutic target for NSCLC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.